Key facts
- Reshape Biotech’s last known valuation is $1.8M (Jan 2021).
- It has raised $29.4M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Y Combinator, Charles Songhurst, FundersClub, ACME Capital, Astanor — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Reshape Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Reshape Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reshape Biotech
Developer of lab automation robots designed to digitize microbiological research workflows. The company offers automated plate imaging devices, AI-driven assay analysis, smart incubators with time-lapse imaging, and a cloud-based data platform, enabling biotech companies and research laboratories to standardize experiments and manage structured data across teams.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2018
- Employees
- 65
- Website
- reshapebiotech.com/
- Ownership
- Privately Held (backing)
Reshape Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reshape Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reshape Biotech in its N-PORT filings yet. We sweep new filings monthly.